The global Kidney Cancer Drugs Market Size is estimated to be valued at US$ 6.2 Bn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Kidney cancer drugs are used for the treatment of renal cell carcinoma (RCC), which is the most common type of kidney cancer in adults. These drugs help improve the survival and quality of life of patients by slowing or stopping the growth and spread of cancerous cells.
Market key trends:
Immunotherapy has emerged as one of the most promising treatment approaches for kidney cancer in recent years. Drugs that boost the body's natural defenses to fight cancer such as checkpoint inhibitors are being increasingly used. Key PD-1 and PD-L1 inhibitors approved for kidney cancer include Opdivo (nivolumab) and Keytruda (pembrolizumab). These drugs have shown superior efficacy compared to existing targeted therapy drugs with tolerable safety profiles. Furthermore, combination immunotherapies using two or more immune checkpoint inhibitors together are gaining traction and demonstrating encouraging response rates in clinical trials for kidney cancer. The better safety profile and durable response rates provided by immunotherapy drugs is expected to drive higher adoption and growth of this segment over the forecast period.
Segment Analysis
The global kidney cancer drugs market is segmented based on drug type, treatment type, end-user, and region. By drug type, the tyrosine kinase inhibitors segment dominated the market in 2022 as these drugs have revolutionized kidney cancer treatment, with better efficacy and tolerability compared to previous therapies. Tyrosine kinase inhibitors effectively inhibit vascular endothelial growth factor receptors and are used as first-line treatment for advanced and metastatic renal cell carcinoma.
Key Takeaways
The global kidney cancer drugs market is expected to witness high growth, exhibiting a CAGR of 6.4% over the forecast period, due to increasing incidence of kidney cancer and the adoption of advanced targeted therapies.
Regional analysis
Regionally, North America dominated the global kidney cancer drugs market in 2022 and is expected to retain its dominance over the forecast period. Higher awareness regarding the early detection of kidney cancer and the strong presence of key market players in the region is responsible for its large share.
Key players
Key players operating in the kidney cancer drugs market are Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc. These players are focusing on developing advanced targeted therapies to expand their product portfolios.
